These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 17875547)
1. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Céspedes-Cruz A; Gutiérrez-Suárez R; Pistorio A; Ravelli A; Loy A; Murray KJ; Gerloni V; Wulffraat N; Oliveira S; Walsh J; Penades IC; Alpigiani MG; Lahdenne P; Saad-Magalhães C; Cortis E; Lepore L; Kimura Y; Wouters C; Martini A; Ruperto N; Ann Rheum Dis; 2008 Mar; 67(3):309-14. PubMed ID: 17875547 [TBL] [Abstract][Full Text] [Related]
2. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Ruperto N; Murray KJ; Gerloni V; Wulffraat N; de Oliveira SK; Falcini F; Dolezalova P; Alessio M; Burgos-Vargas R; Corona F; Vesely R; Foster H; Davidson J; Zulian F; Asplin L; Baildam E; Consuegra JG; Ozdogan H; Saurenmann R; Joos R; Pistorio A; Woo P; Martini A; Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217 [TBL] [Abstract][Full Text] [Related]
3. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Oliveira S; Ravelli A; Pistorio A; Castell E; Malattia C; Prieur AM; Saad-Magalhães C; Murray KJ; Bae SC; Joos R; Foeldvari I; Duarte-Salazar C; Wulffraat N; Lahdenne P; Dolezalova P; de Inocencio J; Kanakoudi-Tsakalidou F; Hofer M; Nikishina I; Ozdogan H; Hashkes PJ; Landgraf JM; Martini A; Ruperto N; Arthritis Rheum; 2007 Feb; 57(1):35-43. PubMed ID: 17266064 [TBL] [Abstract][Full Text] [Related]
4. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Vilca I; Munitis PG; Pistorio A; Ravelli A; Buoncompagni A; Bica B; Campos L; Häfner R; Hofer M; Ozen S; Huemer C; Bae SC; Sztajnbok F; Arguedas O; Foeldvari I; Huppertz HI; Gamir ML; Magnusson B; Dressler F; Uziel Y; van Rossum MA; Hollingworth P; Cawkwell G; Martini A; Ruperto N; Ann Rheum Dis; 2010 Aug; 69(8):1479-83. PubMed ID: 20525842 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Gutiérrez-Suárez R; Pistorio A; Cespedes Cruz A; Norambuena X; Flato B; Rumba I; Harjacek M; Nielsen S; Susic G; Mihaylova D; Huemer C; Melo-Gomes J; Andersson-Gare B; Balogh Z; De Cunto C; Vesely R; Pagava K; Romicka AM; Burgos-Vargas R; Martini A; Ruperto N; Rheumatology (Oxford); 2007 Feb; 46(2):314-20. PubMed ID: 16877459 [TBL] [Abstract][Full Text] [Related]
6. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Albers HM; Wessels JA; van der Straaten RJ; Brinkman DM; Suijlekom-Smit LW; Kamphuis SS; Girschick HJ; Wouters C; Schilham MW; le Cessie S; Huizinga TW; Ten Cate R; Guchelaar HJ Arthritis Rheum; 2009 Jan; 61(1):46-51. PubMed ID: 19116975 [TBL] [Abstract][Full Text] [Related]
7. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525 [TBL] [Abstract][Full Text] [Related]
8. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Bartoli M; Tarò M; Magni-Manzoni S; Pistorio A; Traverso F; Viola S; Magnani A; Gasparini C; Martini A; Ravelli A Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217 [TBL] [Abstract][Full Text] [Related]
9. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B; J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012 [TBL] [Abstract][Full Text] [Related]
10. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155 [TBL] [Abstract][Full Text] [Related]
11. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. Alsufyani K; Ortiz-Alvarez O; Cabral DA; Tucker LB; Petty RE; Malleson PN J Rheumatol; 2004 Jan; 31(1):179-82. PubMed ID: 14705239 [TBL] [Abstract][Full Text] [Related]
12. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Becker ML; van Haandel L; Gaedigk R; Lasky A; Hoeltzel M; Stobaugh J; Leeder JS Arthritis Rheum; 2010 Jun; 62(6):1803-12. PubMed ID: 20191581 [TBL] [Abstract][Full Text] [Related]
13. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385 [TBL] [Abstract][Full Text] [Related]
14. Measuring health status in early juvenile idiopathic arthritis: determinants and responsiveness of the child health questionnaire. Selvaag AM; Flatø B; Lien G; Sørskaar D; Vinje O; Førre Ø J Rheumatol; 2003 Jul; 30(7):1602-10. PubMed ID: 12858465 [TBL] [Abstract][Full Text] [Related]
15. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. Riddle R; Ryser CN; Morton AA; Sampson JD; Browne RH; Punaro MG; Gatchel RJ J Pediatr Psychol; 2006 Apr; 31(3):262-71. PubMed ID: 15872147 [TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life, physical function, fatigue, and disease activity in children with established polyarticular juvenile idiopathic arthritis. Ringold S; Wallace CA; Rivara FP J Rheumatol; 2009 Jun; 36(6):1330-6. PubMed ID: 19411394 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553 [TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004 [TBL] [Abstract][Full Text] [Related]